436 related articles for article (PubMed ID: 33918147)
21. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
22. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
23. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Dempke WCM; Fenchel K; Dale SP
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S275-S279. PubMed ID: 30393621
[TBL] [Abstract][Full Text] [Related]
24. Clinical Correlations of Programmed Cell Death Ligand 1 Status in Liquid and Standard Biopsies in Breast Cancer.
Jacot W; Mazel M; Mollevi C; Pouderoux S; D'Hondt V; Cayrefourcq L; Bourgier C; Boissiere-Michot F; Berrabah F; Lopez-Crapez E; Bidard FC; Viala M; Maudelonde T; Guiu S; Alix-Panabières C
Clin Chem; 2020 Aug; 66(8):1093-1101. PubMed ID: 32712650
[TBL] [Abstract][Full Text] [Related]
25. Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges.
Rijavec E; Coco S; Genova C; Rossi G; Longo L; Grossi F
Cancers (Basel); 2019 Dec; 12(1):. PubMed ID: 31861557
[TBL] [Abstract][Full Text] [Related]
26. Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.
Levy B; Hu ZI; Cordova KN; Close S; Lee K; Becker D
Oncologist; 2016 Sep; 21(9):1121-30. PubMed ID: 27388233
[TBL] [Abstract][Full Text] [Related]
27. The Overview of Perspectives of Clinical Application of Liquid Biopsy in Non-Small-Cell Lung Cancer.
Bożyk A; Nicoś M
Life (Basel); 2022 Oct; 12(10):. PubMed ID: 36295075
[TBL] [Abstract][Full Text] [Related]
28. Diagnostic and prognostic role of liquid biopsy in non-small cell lung cancer: evaluation of circulating biomarkers.
Vicidomini G; Cascone R; Carlucci A; Fiorelli A; Di Domenico M; Santini M
Explor Target Antitumor Ther; 2020; 1(5):343-354. PubMed ID: 36046486
[TBL] [Abstract][Full Text] [Related]
29. PD-L1
Zhang L; Zhang X; Liu Y; Zhang T; Wang Z; Gu M; Li Y; Wang DD; Li W; Lin PP
Cancer Lett; 2020 Jan; 469():355-366. PubMed ID: 31678168
[TBL] [Abstract][Full Text] [Related]
30. The role of circulating free DNA in the management of NSCLC.
Esposito Abate R; Pasquale R; Fenizia F; Rachiglio AM; Roma C; Bergantino F; Forgione L; Lambiase M; Sacco A; Piccirillo MC; Morabito A; Normanno N
Expert Rev Anticancer Ther; 2019 Jan; 19(1):19-28. PubMed ID: 30462523
[TBL] [Abstract][Full Text] [Related]
31. The prognostic significance of circulating tumor cells in head and neck and non-small-cell lung cancer.
Kulasinghe A; Kapeleris J; Kimberley R; Mattarollo SR; Thompson EW; Thiery JP; Kenny L; O'Byrne K; Punyadeera C
Cancer Med; 2018 Dec; 7(12):5910-5919. PubMed ID: 30565869
[TBL] [Abstract][Full Text] [Related]
32. The Emerging Role of Liquid Biopsy in Gastric Cancer.
Lengyel CG; Hussain S; Trapani D; El Bairi K; Altuna SC; Seeber A; Odhiambo A; Habeeb BS; Seid F
J Clin Med; 2021 May; 10(10):. PubMed ID: 34068319
[TBL] [Abstract][Full Text] [Related]
33. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
34. PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system
Raimondi C; Carpino G; Nicolazzo C; Gradilone A; Gianni W; Gelibter A; Gaudio E; Cortesi E; Gazzaniga P
Oncoimmunology; 2017; 6(12):e1315488. PubMed ID: 29209560
[TBL] [Abstract][Full Text] [Related]
35. Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer.
Duchemann B; Remon J; Naigeon M; Mezquita L; Ferrara R; Cassard L; Jouniaux JM; Boselli L; Grivel J; Auclin E; Desnoyer A; Besse B; Chaput N
Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33287347
[TBL] [Abstract][Full Text] [Related]
36. Machine learning reveals a PD-L1-independent prediction of response to immunotherapy of non-small cell lung cancer by gene expression context.
Wiesweg M; Mairinger F; Reis H; Goetz M; Kollmeier J; Misch D; Stephan-Falkenau S; Mairinger T; Walter RFH; Hager T; Metzenmacher M; Eberhardt WEE; Zaun G; Köster J; Stuschke M; Aigner C; Darwiche K; Schmid KW; Rahmann S; Schuler M
Eur J Cancer; 2020 Nov; 140():76-85. PubMed ID: 33059196
[TBL] [Abstract][Full Text] [Related]
37. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
38. Assessment of the PD-L1 status by immunohistochemistry: challenges and perspectives for therapeutic strategies in lung cancer patients.
Ilie M; Hofman V; Dietel M; Soria JC; Hofman P
Virchows Arch; 2016 May; 468(5):511-25. PubMed ID: 26915032
[TBL] [Abstract][Full Text] [Related]
39. Liquid Biopsy in Lung Cancer: Clinical Applications of Circulating Biomarkers (CTCs and ctDNA).
Lim M; Kim CJ; Sunkara V; Kim MH; Cho YK
Micromachines (Basel); 2018 Feb; 9(3):. PubMed ID: 30424034
[TBL] [Abstract][Full Text] [Related]
40. Current Status and Future Perspectives of Liquid Biopsy in Small Cell Lung Cancer.
Mondelo-Macía P; García-González J; León-Mateos L; Castillo-García A; López-López R; Muinelo-Romay L; Díaz-Peña R
Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33430290
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
